Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial

This phase 3 clinical trial evaluated the efficacy of linaclotide specifically in irritable bowel syndrome with constipation (IBS-C), a condition combining chronic abdominal pain with altered bowel habits. The study included 804 patients randomized to linaclotide 290 mcg or placebo once daily for 26 weeks, followed by a 4-week washout period.

The results demonstrated significant superiority of linaclotide over placebo in the composite primary endpoint that included simultaneous improvement in abdominal pain and bowel movement frequency: 33.7% of linaclotide patients were responders versus only 13.9% in the placebo group (p<0.001). The improvement in abdominal pain is particularly relevant, as linaclotide acts not only on motility but also on visceral hypersensitivity.

The analgesic mechanism involves the production of extracellular cyclic GMP by the GC-C receptor, which acts on afferent nerves of the colonic mucosa, reducing nociceptive signaling. This dual mechanism — pro-secretory and analgesic — differentiates linaclotide from other constipation treatments.

During the washout period, symptoms gradually returned to baseline, confirming that the effect is dependent on continuous use. The safety profile was consistent with previous studies, with diarrhea as the main adverse effect (19.7% vs 3.2% placebo). These data contributed to the approval of linaclotide as the first GC-C agonist indicated for IBS-C.